Hot Pharma Stocks / Ideen / Blockbuster

  • TSPT 6.70$

    Transcept Intermezzo Approved by FDA


  • INHX 16.15$

    External Content
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

    rocket science!


    Bio-pharmaceutical company Inhibitex, Inc.'s (NASDAQ: INHX ) shares advanced 20.18% to close at $13.70 after the company announced it plans to expand studies of its experimental hepatitis C treatment

    Read more:…ryid=105851#ixzz1fJ9smOrJ

  • PLX

    Protalix Announces Successful European GMP Audit


    CARMIEL, Israel, Dec. 1, 2011 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX, TASE:PLX), announced today that the Irish Medicines Board (IMB) has completed a successful GMP (Good Manufacturing Practice) audit of the Company's manufacturing facility in Carmiel, Israel, and has issued a Certificate of GMP Compliance of a Manufacturer for the facility. The IMB Certificate is accepted by all health authorities in the European Union (EU) under the EU's centralized marketing authorization procedure, and by authorities of several other countries that recognize EU Certification. The audit was performed as part of the European Medicines Agency's (EMA) evaluation of the Marketing Authorization Application for taliglucerase alfa for the treatment of Gaucher disease.

    In addition to the EMA, the U.S. Food and Drug Administration (FDA), Israeli Ministry of Health and Brazilian National Health Surveillance Agency have completed audits of the Company's manufacturing facility and deemed the facility acceptable.

    "We are pleased to accomplish this major regulatory milestone," said Dr. Michal Kahana, Protalix's Vice President of Quality Affairs. "This important achievement helps demonstrate the viability of our proprietary plant-cell based technology platform, which is the engine behind all our pipeline candidates."

    To date, marketing applications for taliglucerase alfa have been submitted in the United States, European Union, Brazil, Israel and Australia. The Prescription Drug User Fee Act (PDUFA) target date for taliglucerase alfa in the United States is February 1, 2012.

    [Blocked Image:]

  • Hot Pharma Stocks / Ideen / Blockbuster

    b00n wrote:

    was geht da?

    Peregrine Pharmaceuticals(NASDAQ:PPHM)

    P2 Daten

    Peregrine's Bavituximab Shows 50% Improvement in Overall Tumor Response Rate in Randomized Phase II Lung Cancer Trial

    200dma @ 1.70$ aktuell

    gap offen bei 0.99$

  • ALXA 0.52$

    Alexza Inhaled Antipsychotic May Pose Fatal Lung Risks, FDA Review Finds


  • AIS 2.50$

    Antares' Oxybutynin Gel Product Approved by FDA for the Treatment of Overactive Bladder


  • AFFY 8.00$

    Affymax Rises After Winning Panel’s Backing for Anemia Drug


  • CYTR 0.32$

    CytRx's ENABLE Phase 2 Trial Results with Bafetinib in Relapsed B-Cell Chronic Lymphocytic Leukemia to be Presented at the Prestigious 53rd Annual ASH Meeting


  • CYTR 0.33$

    Hab 1000 CYTR gekauft gerade eben zu 0.334$. Hoffe auf gute Phase 2 Daten von der ASH Konferenz am Sonntag.

    Ziel nach oben 0.50$

    Ziel nach unten 0.19$

    Die Firma hat 40Millionen Cash auf der Seite, hat mitte 2011 Geld aufgenommen zu 0.50$ je Aktie und hat keine Schulden. CYTR hat 0.28$ cash per share und einen Buchwert von 0.19$.

  • Hot Pharma Stocks / Ideen / Blockbuster

    b00n wrote:

    BPAX und das libido gel is grad an die wand geknallt..

    und hier die quittung. tagesdurchschnittsvolumen in 1 minute erreicht zu dem kurs:


    -1.605 (-75.71%)

    folglich auch AIS angeschlagen:


    -0.65 (-26.97%)

    jetzt dürfen die hardcore gamer ran und den besten einstieg finden. allerdings weiss ich nicht, was BPAX noch zu bieten hätte ausser libigel (nahe zukunft that is)